XOMA (XOMA Royalty) Other Stockholders Equity: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XOMA XOMA Royalty Corp XOMA
41 GF Score
Price $40.17
GF Value $18.93
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is XOMA Royalty Other Stockholders Equity?

XOMA Royalty XOMA -0.10% 41 Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus rates XOMA with a GF Score™ of 41/100 and a GF Value™ of $18.93 (Significantly Overvalued). The stock has 8 warning signs investors should review.

XOMA Royalty's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

XOMA Royalty's quarterly Other Stockholders Equity increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil) and increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

XOMA Royalty's annual Other Stockholders Equity increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

XOMA Royalty Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for XOMA Royalty's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XOMA Royalty Other Stockholders Equity Chart

XOMA Royalty Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XOMA Royalty Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00
XOMA
41GF Score
XOMA Royalty Corp XOMA
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XOMA Royalty Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
XOMA Royalty (XOMA) has a Other Stockholders Equity of $0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on XOMA Royalty and its competitors.
Is XOMA Royalty's Other Stockholders Equity too high?
XOMA Royalty's current Other Stockholders Equity is $0.00 Mil. Overall, XOMA Royalty has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's Other Stockholders Equity compare to CLYM and CTMX?
XOMA Royalty's Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on XOMA Royalty and its competitors. XOMA Royalty's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.93, compared to a current price of $40.17 — trading 112.2% above its estimated fair value. The current Other Stockholders Equity is $0.00 Mil. XOMA Royalty's overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is XOMA Royalty (XOMA) Overvalued in 2026?

Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued. The current stock price of $40.17 is trading 112.2% above its estimated GF Value™ of $18.93. GuruFocus considers XOMA Royalty to be Significantly Overvalued.

Key valuation signals for XOMA:

  • Other Stockholders Equity: $0.00 Mil
  • GF Value™: $18.93 vs. price of $40.17 (112.2% above fair value)
  • GF Score™: 41/100 with 8 warning signs

No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XOMA Royalty Business Description

Address 2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
41GF Score

Get the complete analysis for XOMA

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.17
Price
$18.93
GF Value